Maximum Request. The general unpaid leave of absence period shall not exceed ninety (90) days. An employee, who has completed his/her probationary period, who is unable to perform his/her duties because of illness or injury and who has exhausted all ELB & PTO, may upon request, be granted a leave of absence, without pay, of up to one (1) year.
Maximum Request. The general unpaid leave of absence period shall not exceed ninety (90) days.
Maximum Request. Subject to Section 5.10(c) below, beginning on [*] and continuing through [*], the annual Maximum Request in Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been submitted to the Securities and Exchange Commission.
Maximum Request. BIP shall provide Immunex and Wyeth with reserved production capacity, including lyophilization and filling capacity, for Bulk Drug Substance, Drug Product and Finished Product for the Supply Term based on the initial Maximum Request of [*] ([*]) kg per Calendar Year, provided that Buyer may issue Firm Orders for Bulk Drug Substance, Drug Product and/or Finished Product greater than such amount to the extent BIP's free available production capacity for Bulk Drug Substance, Drug Product and/or Finished Product exceeds [*] ([*]) kg per Calendar Year. The Parties acknowledge and agree that the initial Maximum Request of [*] ([*]) kg of Bulk Drug Substance per Calendar Year is based on the initial Production Assumptions set forth in Section 5.3(a) hereof, and the assumption as of the Effective Date that a total of [*] ([*]) Bulk Drug Substance Runs initially reserved for Immunex and Wyeth [*]. The Parties also understand, however, that BIP's actual production of Bulk Drug Substance could be either more or less than [*] ([*]) kg per Calendar Year, depending on such factors as the actual success rate, fermentation crude Product titer, and purification yield.
Maximum Request. Subject to Section 5.10(c) below, beginning on [*] and continuing through [*], the annual Maximum Request in the Agreement shall be equal to the Annual Minimum as defined in Section 5.10(b) below. Beginning [*], or as otherwise set forth in Section 5.10(c) below, the Maximum Request shall revert to the terms in the original Agreement. Immunex and Wyeth shall waive their ability to reduce the Maximum Request below the Annual Minimum under Section 5.1(b) hereof until an effective date of [*] at the earliest, except to the extent otherwise permitted in Section 5.10(c) below. Subject to Section 5.10(c) below, beginning on [*] and continuing through the [*] Confidential Treatment Requested
Maximum Request. Subject to Section 5.10(c) below, beginning on [*] and continuing through [*], the annual Maximum Request in the Agreement shall be equal to the Annual Minimum as defined in Section 5.10(b) below. Immunex and Wyeth hereby waive their ability to reduce the Maximum Request below the Annual Minimum under Section 5.1(b) hereof until an effective date of [*] at the earliest, except to the extent otherwise permitted in Section 5.10(c) below. Subject to Section 5.10(c) below, beginning on [*] and continuing through the end of the Supply Term, Immunex and Wyeth shall be entitled to reduce the Maximum Request (unless otherwise agreed in writing among the Parties, to be calculated by using the original Maximum *Confidential Treatment Requested. Request herein) by no more than [*] percent ([*]%) per Calendar Year by providing at least the required [*] prior written notice to BIP (e.g., notice by [*] for a potential reduction in the Maximum Request effective as of [*], etc.). Moreover, the absolute minimum of the Maximum Request after permitted reductions under Section 5.1(b) of the original Agreement shall always be the required capacity for [*] of Bulk Drug Substance calculated in accordance with the original Production Assumptions herein. In addition to the Maximum Request, BIP shall be bound to provide the following Bulk Drug Substance Runs in the Original Biberach Facility to Immunex and Wyeth:
